Vidarbha News

Acute Intermittent Porphyria Market is expected to Grow during Forecast Period (2023-2032), Investigates DelveInsight | Companies- Dahaner, Roche, Bio-Rad Laboratories, Siemens, ARKRAY

 Breaking News
  • No posts were found

Acute Intermittent Porphyria Market is expected to Grow during Forecast Period (2023-2032), Investigates DelveInsight | Companies- Dahaner, Roche, Bio-Rad Laboratories, Siemens, ARKRAY

September 14
14:26 2023
Acute Intermittent Porphyria Market is expected to Grow during Forecast Period (2023-2032), Investigates DelveInsight | Companies- Dahaner, Roche, Bio-Rad Laboratories, Siemens, ARKRAY
Acute Intermittent Porphyria Market

DelveInsight’s “Acute Intermittent Porphyria Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Acute Intermittent Porphyria, historical and forecasted epidemiology as well as the Acute Intermittent Porphyria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To know more about the Acute Intermittent Porphyria market report offering, click here: Acute Intermittent Porphyria Market Insight

 

Some Key facts of Acute Intermittent Porphyria Market are:

  • According to the WHO estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies.
  • According to the American Liver Foundation, there is an increasing the prevalence of liver disease in the U.S. from then last few years. It further stated that at least 30 million people have some form of liver disease.
  • The growing awareness about porphyria and growth of the healthcare sector in emerging countries are the major drivers for the acute intermittent porphyria market.
  • The United States holds the highest Acute Intermittent Porphyria market share in 7MM.
  • Some of the Acute Intermittent Porphyria companies working in the market are Dahaner, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Siemens AG, ARKRAY, Sysmex Corporation, ACON Laboratories, Inc., Alnylam Pharmaceuticals, Digna Biotech S.L, Zymenex A/S, Chiesi Farmaceutici S.p.A. and several others.

 

Acute Intermittent Porphyria Overview:

Acute Intermittent Porphyria (AIP) is a rare genetic disorder characterized by a deficiency of an enzyme called porphobilinogen deaminase (PBGD), which is essential for the production of heme, a component of hemoglobin. Acute Intermittent Porphyria primarily affects the nervous system and can manifest with severe, intermittent attacks of abdominal pain, neuropathy, muscle weakness, and neuropsychiatric symptoms.

These attacks can be triggered by various factors, such as certain medications, hormonal changes, or dietary choices. Diagnosis often involves measuring porphyrin levels in the urine, genetic testing, and clinical evaluation during an acute episode. Management of Acute Intermittent Porphyria includes avoiding triggers, providing symptomatic relief during attacks, and, in some cases, administering heme therapy to alleviate symptoms.

Early diagnosis and appropriate management are crucial to prevent life-threatening complications during acute episodes. While Acute Intermittent Porphyria is a lifelong condition, many individuals with the disorder can lead normal lives with proper care and awareness of their triggers.

 

To know in detail about the Acute Intermittent Porphyria epidemiological trends and market dynamics, click here: https://www.delveinsight.com/sample-request/acute-intermittent-porphyria-market

 

Scope of Acute Intermittent Porphyria Market Report:

  • The report covers the descriptive overview of Acute Intermittent Porphyria, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies.
  • Comprehensive insight has been provided into the Acute Intermittent Porphyria epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Acute Intermittent Porphyria are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Acute Intermittent Porphyria market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute Intermittent Porphyria market.

 

To know in detail about the Acute Intermittent Porphyria companies working in the market, click here: Acute Intermittent Porphyria Market Trends

 

Acute Intermittent Porphyria Companies are:

  • Dahaner
  • F. Hoffmann-La Roche Ltd
  • Bio-Rad Laboratories, Inc.
  • Siemens AG
  • ARKRAY, Inc.
  • Sysmex Corporation
  • ACON Laboratories, Inc.
  • Alnylam Pharmaceuticals
  • Digna Biotech S.L
  • Zymenex A/S
  • Chiesi Farmaceutici S.p.A.
  • And Many More

 

Acute Intermittent Porphyria Therapies are:

  • Givosiran
  • Recombinant human porphobilinogen deaminase (Porphozym)
  • ALN-AS1
  • And Many More

 

Request for Free Sample Report to know in detail about the recent developments in Acute Intermittent Porphyria clinical trials and therapeutic assessment: https://www.delveinsight.com/sample-request/acute-intermittent-porphyria-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Acute Intermittent Porphyria

3. Competitive Intelligence Analysis for Acute Intermittent Porphyria

4. Acute Intermittent Porphyria: Market Overview at a Glance

5. Acute Intermittent Porphyria: Disease Background and Overview

6. Acute Intermittent Porphyria Patient Journey

7. Acute Intermittent Porphyria Epidemiology and Patient Population

8. Acute Intermittent Porphyria Treatment Algorithm, Current Treatment, and Medical Practices

9. Acute Intermittent Porphyria Unmet Needs

10. Key Endpoints of Acute Intermittent Porphyria Treatment

11. Acute Intermittent Porphyria Marketed Products

List to be continued in report

12. Emerging Acute Intermittent Porphyria Therapies

List to be continued in report

13. Acute Intermittent Porphyria: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Acute Intermittent Porphyria Market Outlook

16. Access and Reimbursement Overview of Acute Intermittent Porphyria

17. KOL Views

18. Acute Intermittent Porphyria Market Drivers

19. Acute Intermittent Porphyria Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market

About Author

admin

admin

Categories